US FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy